The analysis of pharmacokinetic and pharmacogenomic impact on gefitinib efficacy in advanced non-small cell lung cancer patients: results from a prospective cohort study.

ABSTRACT:

Background

The current study is aimed to examine the impact of pharmacokinetics and gene polymorphisms of enzymes involving in absorption, distribution, metabolism and excretion (ADME) on the efficacy of gefitinib in non-small cell lung cancer (NSCLC) patients.

Methods

Eligible patients with indication of gefitinib treatment were prospectively enrolled in this study. Two peripheral blood samples at baseline and before cycle 2 day 1 were collected for the detection of single nucleotide polymorphisms (SNPs) of drug ADME enzymes and trough drug concentration (C_trough) at steady state. Thirteen SNPs were genotyped using the Sequenom Massarray system. C_trough was determined by validated high-performance liquid chromatographic method with tandem mass spectrom

SUBMITTER: Ma Y 

PROVIDER: S-EPMC6989872 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature